InMed Pharmaceuticals (OTCMKTS:IMLFF) provided an update on the progress of its lead product INM-750 for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder. The company reported that INM-750 has demonstrated positive effects in pre-clinical studies on wound healing and in inflammation.
As quoted in the press release:
INM-750 is a topical formulation of phytocannabinoids that have been carefully selected using our proprietary bioinformatics discovery platform to treat: (i) the underlying cause of the disease in patients with epidermolysis bullosa simplex (the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.
InMed’s initial pre-clinical studies were focused on studying the potential of INM-750 to treat the cause of the disease by modulating the expression of the various keratins that are critical to maintaining the integrity of the skin. We have previously reported that InMed has been able to demonstrate that certain phytocannabinoids are able to positively influence the expression of the key keratins K5, K6, K14, K15 and K16. We continue to make progress in studying the effect of different cannabinoids at different doses on keratin expression, and a summary of our initial results are now available on our website.
World High Life Plc (“World High Life” or the “Company”)(AQSE:LIFE) (OTCQB:WRHLF), is pleased to announce that it has appointed H&P Advisory Limited (“Hannam & Partners”) as financial advisor to the Company with immediate effect
About Love Hemp
Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ retail stores, today announced that its executive team will participate in the following conference in March 2021:
Needham 2 nd Annual Virtual Cannabis Conference, March 3, 2021: Management will participate in one-on-one meetings.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.